Valeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler®

Rhea-AI Summary

Valeo Pharma has announced that 80% of private payer health plans in Canada now cover Enerzair Breezhaler and Atectura Breezhaler, two new asthma treatments. The company is set to begin reimbursement proceedings with public health plans. Both therapies have shown significant clinical improvement in asthma symptoms and lung function compared to standard care. This advancement is crucial as private payers cover 50% of the asthma treatment market in Canada, potentially increasing accessibility for patients.

Positive

• 80% private payer coverage for Enerzair Breezhaler and Atectura Breezhaler in Canada.
• Reimbursement proceedings with public health plans ready to start.
• Both drugs have demonstrated significant clinical improvements versus standard care.

Negative

• None.

• Private payer health plan coverage in Canada for Enerzair Breezhaler and Atectura Breezhaler has reached 80%
  
  
• Reimbursement proceedings with publicly funded health plans ready to commence

MONTREAL, June 1, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that private payer health plans currently covering 80% of privately insured lives in Canada have agreed to provide reimbursement for Enerzair Breezhaler and Atectura Breezhaler.

Enerzair Breezhaler and Atectura Breezhaler are two new innovative asthma therapies which have been approved for use in Canada. 

"Asthma therapies are largely covered by private payers representing 50% of the total market. Reimbursement of both Enerzair and Atectura are now available for the majority of privately covered lives in Canada and reimbursement proceedings with public health plans are  ready to commence", said Frederic Fasano, Valeo's President and Chief Operating Officer. "Both drugs have demonstrated, in head-to-head compararison versus standard of care, significant clinical improvement of asthma related symptoms, lung function and rate of exacerbations. These strong clinical value propositions were key in achieving the current level of private coverage".

About Enerzair Breezhaler  

Enerzair Breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta₂-agonist and a medium or high dose of an inhaled corticosteroid. This formulation combines the bronchodilation of indacaterol acetate (a LABA) and the glycopyrronium bromide (a LAMA) with mometasone furoate (an ICS) in a precise once-daily formulation, delivered via the dose-confirming Breezhaler device.

About Atectura Breezhaler        

Atectura Breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease. Atectura Breezhaler should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as ICS or whose disease severity clearly warrants treatment with both a LABA and an ICS. Atectura Breezhaler combines the bronchodilation of indacaterol acetate (a LAMA) with the anti-inflammatory mometasone furoate (an ICS) in a precise once-daily formulation, delivered via the dose-confirming Breezhaler device.

About Valeo Pharma

Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology, Neurodegenerative Diseases, Oncology and other specialty products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter. 

Forward Looking Statements

This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

View original content to download multimedia:http://www.prnewswire.com/news-releases/valeo-pharma-provides-update-on-private-payer-reimbursement-for-enerzair-breezhaler-and-atectura-breezhaler-301302764.html

SOURCE Valeo Pharma Inc.

FAQ

What percentage of private health plans cover VPHIF's asthma medications in Canada?

As of June 1, 2021, 80% of private payer health plans in Canada cover Enerzair Breezhaler and Atectura Breezhaler.

What are the key benefits of Enerzair Breezhaler and Atectura Breezhaler?

Both medications have shown significant clinical improvements in asthma symptoms and lung function compared to standard treatments.

Is Valeo Pharma planning to start reimbursements with public health plans for VPHIF products?

Yes, Valeo Pharma is preparing to commence reimbursement proceedings with publicly funded health plans.

What market share do private payers represent for asthma therapies in Canada?

Private payers represent approximately 50% of the total asthma therapy market in Canada.